After having warned that it could lose up to 94% of its staff in a relocation from its current home in London, United Kingdom, The European Medicines Agency (EMA) this week revealed its top location choices for the agency’s upcoming move.
After having warned that it could lose up to 94% of its staff in a relocation from its current home in London, United Kingdom, The European Medicines Agency (EMA) this week revealed its top location choices for the agency’s upcoming move.
The EMA rated each of the cities proposing to host the agency in terms of technical requirements (including building layouts and relocation planning), additional criteria (including accessibility of each location, resources for families of staffers, and business continuity), and the likelihood of retaining the most personnel. Vying for the EMA are Amsterdam, Netherlands; Athens, Greece; Barcelona, Spain; Bonn, Germany; Bratislava, Slovakia; Brussels, Belgium; Bucharest, Romania; Copenhagen, Denmark; Dublin, Ireland; Helsinki, Finland; Lille, France; Malta; Milan, Italy; Porto, Portugal; Sofia, Bulgaria; Stockholm, Sweden; Vienna, Austria; Warsaw, Poland; and Zagreb, Croatia.
The cities that earned top marks for meeting the EMA's technical requirements were the following:
Each of the above cities met some of the agency’s requirements, though the EMA had concerns about timely operation at each of the locations. Sofia and Malta earned the lowest ratings in this category.
In terms of its additional criteria, the EMA gave Vienna top marks, with Amsterdam, Barcelona, Copenhagen, Milan also ranked highly.
The cities in which the EMA was likely to retain 65% or more of its staff, based on feedback from its workers, were the following:
The cities where the agency could expect to retain less than 30% of its staff were the following:
While the EMA rated Barcelona highly in each of its categories, political unrest in Catalonia could take a toll on the city’s ability to secure the regulatory body's presence. Last week’s vote on independence for the Catalonia region was met with a show of Spanish police force that left hundreds of civilians injured. On Friday, Spain’s government began to ease restrictions on businesses seeking to leave Barcelona and other Catalonian areas in order to remain in the Eurozone in the event of a Catalonian secession; should Catalonia become an independent nation, it would not automatically retain membership in the European Union, and Barcelona could become just as untenable a long-term home for the EMA as London was.
The EMA has provided its report to the European Commission, which will determine the agency’s new location in a vote held next month.
13 Strategies to Avoid the Nocebo Effect During Biosimilar Switching
December 18th 2024A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared decision-making, to mitigate the nocebo effect in biosimilar switching, emphasizing the need for a multifaceted approach to improve patient perceptions and therapeutic outcomes.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Withdrawal of Proposed Terminal Disclaimer Rule Spells Major Setback for Biosimilars
December 10th 2024The United States Patent and Trademark Office (USPTO)’s withdrawal of its proposed terminal disclaimer rule is seen as a setback for biosimilar developers, as it preserves patent prosecution practices that favor originator companies and increases costs for biosimilar competition, according to Sarfaraz K. Niazi, PhD.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Perceptions of Biosimilar Switching Among Veterans With IBD
December 2nd 2024Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in biosimilar switching, favoring delayed switching for severe cases and greater patient control.